Renaissance Capital logo

Instil Bio Priced, Nasdaq: TIL

Early stage biotech developing immune cell therapies for cancer.

Industry: Health Care

Latest Trade: $11.50 0.00 (0.0%)

First Day Return: +32.2%

Return from IPO: -97.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. We have assembled an accomplished team with a successful track record in the development, manufacture, regulatory approval and commercialization of multiple cell therapies. Using our optimized and scalable manufacturing process, we are advancing our lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. Based on the clinical results from a compassionate use program with a TIL product that was manufactured using a prior version of the ITIL-168 manufacturing process, we plan to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or the FDA, and, if authorized to proceed, initiate a Phase 2 trial in the second half of 2021, which we believe could support a BLA submission in 2023. We plan to initiate Phase 1 trials of ITIL-168 in additional indications with unmet medical need, including cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck cancer and cervical cancer, in the first half of 2022.
more less
IPO Data
IPO File Date 02/26/2021
Offer Price $20.00
Price Range $19.00 - $20.00
Offer Shares (mm) 16.0
Deal Size ($mm) $320
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/18/2021
Offer Price $20.00
Price Range $19.00 - $20.00
Offer Shares (mm) 16.0
Deal Size ($mm) $320
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
Jefferies
more
Company Data
Headquarters Dallas, TX, United States
Founded 2018
Employees 150
Website instilbio.com

Instil Bio (TIL) Performance